Almac, PILA PHARMA Enter API Manufacturing Pact
Almac will manufacture XEN-D0501, a highly selective and very potent small molecule TRPV1 antagonist for ongoing type 2 diabetes clinical studies.
August 12, 2021
by contractpharma
Almac, THREAD to Integrate Technologies for Clinical Trials
Integrating technology platforms aims to provide sponsors and CROs with a full range of tools designed to reduce the risk of trial delays.
July 29, 2021
by contractpharma
Almac's Charnwood site achieves H&S and environmental certification
The CDMO plans to roll out the ISO 45001 and ISO 14001 certification throughout multiple sites worldwide
July 12, 2021
by prnewswire
Almac’s Charnwood Site Receives ISO Certifications
Achieves globally recognized Health & Safety and Environmental Management System certifications.
July 7, 2021
by contractpharma
Almac Invests $830M to Expand Crystallization Capabilities
Almac Sciences has invested approximately $485 million in an automated crystallization platform to support solid form screening of polymorphs, salts and crystals in addition to crystallization of amorphous materials.
July 2, 2021
by contractpharma
Almac Group Completes $7M R&D Center
Almac Sciences, a member of the Almac Group, has completed a roughly $7 million investment in a new two-storey center for biocatalysis, flow chemistry technologies and peptide research and development.
February 24, 2021
by contractpharma
Almac Expands Global Biologics Testing Services
Almac Sciences, a member of the Almac Group, has expanded its biologics testing laboratory with significant investment in mass spectrometry equipment.
January 28, 2021
by contractpharma
Almac Secures Grant for Remdesivir Manufacturing for COVID-19
Almac Sciences has been awarded a grant of approximately $500,000 by the COVID-19 Therapeutics Accelerator towards developing cost effective, scalable processes for the production of the active pharmaceutical ingredient (API) of the drug remdesivir.
December 1, 2020
by americanpharmaceuticalreview
Almac Gets Grant From COVID-19 Therapeutics Accelerator
Almac Sciences has been awarded a grant of approximately $500,000 by the COVID-19 Therapeutics Accelerator towards developing cost effective, scalable processes for the production of the active pharmaceutical ingredient (API) of the drug remdesivir.
November 19, 2020
by contractpharma
Almac Launches Biologics Testing Services
New services include GMP lot release and stability testing to support drug substance and drug product programs for biologics and biosimilars.
September 27, 2020
by contractpharma
Almac Offers Expedited Support for COVID-19 Clinical Trials
Expedited implementation of Interactive Response Technology (IRT) in support of pandemic research efforts.
April 8, 2020
by contractpharma
Almac Awarded $200,000 BMGF Grant
Will work to develop novel biocatalytic routes to Etonorgestrel and Levonorgestrel APIs.
December 11, 2019
by ContractPharma